---
title: When should we use it? The role of brentuximab vedotin in 2024
date: '2024-12-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39644065/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241207173153&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: The CD30-directed antibody-drug conjugate brentuximab vedotin (BV) was
  FDA approved in 2011 for the treatment of relapsed classic Hodgkin lymphoma (cHL),
  in 2015 for maintenance after autologous transplantation in high-risk patients,
  and in 2018 for frontline therapy with doxorubicin, vinblastine, and dacarbazine
  for advanced stage cHL. Although the role of BV in cHL had been reasonably well-established,
  it is currently being challenged by the changing landscape of other highly effective
  ...
disable_comments: true
---
The CD30-directed antibody-drug conjugate brentuximab vedotin (BV) was FDA approved in 2011 for the treatment of relapsed classic Hodgkin lymphoma (cHL), in 2015 for maintenance after autologous transplantation in high-risk patients, and in 2018 for frontline therapy with doxorubicin, vinblastine, and dacarbazine for advanced stage cHL. Although the role of BV in cHL had been reasonably well-established, it is currently being challenged by the changing landscape of other highly effective ...